Prohibition Partners Released Poland Medical Cannabis Market Review

WARSAW – Prohibition Partners has published its Poland Medical Cannabis Market Review 2026, a detailed examination of pharmacy-level sales data through the full year 2025 along with projections for 2026 and 2027.

The report, prepared with input from analyst Alfredo Pascual, draws directly from records maintained by Poland’s Centrum e-Zdrowia. It covers 84 consecutive months of activity beginning in January 2019, the longest continuous official dataset of its kind for the country’s medical Cannabis sector.

Polish pharmacies dispensed 5,447 kilograms of dried Cannabis flower in 2025, an increase of 12% from roughly 4,855 kilograms the year before. Monthly volumes recovered steadily after an initial decline, exceeding earlier peaks by October and setting a new high in December.

Revenue told a different story. Total sales reached about 253 million Polish zloty, or roughly 60 million euros, a decline of 19% from 2024. The drop reflected a 28% reduction in the average price per gram as greater supply met continued demand.

The numbers follow a regulatory change in November 2024. Authorities then required in-person consultations for prescriptions issued through private clinics, ending a period of rapid expansion driven by telemedicine services. Prescriptions and dispensed volumes fell by more than half in the weeks that followed, with Q1 2025 remaining subdued. Clinics responded by adopting structured models, including temporary prescriber locations in smaller cities, which helped restore access over the course of the year.

Poland has permitted medical Cannabis by prescription since 2017 but maintains no meaningful domestic production of Cannabis flower. All products are imported. The market therefore operates entirely on supply from outside the country, a factor that contributes to pricing dynamics visible in the latest figures.

The review includes seven data visualizations and supporting tables in its written section, plus a fully interactive Excel workbook that allows users to adjust assumptions and generate forecasts under bear, base and bull cases.

Extensively, the report offers a clear illustration of how patient demand can persist through access restrictions while market economics adjust to new realities. Volume growth signals steady interest among patients and physicians, yet the revenue contraction points to the effects of competition and supply increases in an import-dependent system. Such primary-source tracking remains essential for operators and investors seeking to gauge outcomes in regulated medical Cannabis programs across Europe.

Images courtesy of prohibitionpartners.com